Abstracts tagged "combination therapies and rheumatoid arthritis (RA)"

Abstract Number: 2194 • 2018 ACR/ARHP Annual Meeting
Develop a New Platform for Post-Marketing Vigilance Though Smart System of Disease Management (SSDM) Mobiles Tools: A Real World Cohort Study of RA Patients from China
Yongfu Wang¹, Hua Wei², Jing Yang³, Chun Li⁴, Rong Mu⁵, Bin Wu⁶, Hongzhi Wang⁷, Yong Wang⁸, Xiaohan Wang⁹, Huifang Guo¹⁰, Jing Xue¹¹, Jinli Ru¹², Xiafei Xin¹³, Fengxiao Zhang¹⁴, Lirong Kang¹, Hong Liu³, Xiaoling Liu¹⁵, Tong Xie¹⁶, Lingxun Shen¹⁷, Huiqin Yang¹⁸, Shouxin Li¹⁹, Fen Li²⁰, Fen Wang²¹, Rui Wu²², Yuan Liu²³, Hui Xiao²³, Yuhua Jia²³, Fei Xiao²³ and Jianlin Huang²⁴, ¹The First Affiliated Hospital of BaoTou Medical College, Baotou, China, ²Northern Jiangsu People's Hospital, Yangzhou, China, ³Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ⁴Peking University People's Hospital, Beijing, China, ⁵Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁶Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China, ⁷The First Hospital of Jiaxing, Jiaxing, China, ⁸The first Hospital Affiliated to AMU (Southernwest Hospital), Chongqing, China, ⁹Department of Rheumatology and Immunology, Anyang district hospital, Anyang, China, ¹⁰The Second Hospital of Hebei Medical University, Shijiazhuang, China, ¹¹88 Jiefang Road, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ¹²The Second hospital of Shanxi Medical University, Taiyuan, China, ¹³Department of Rheumatology and Immunology, NingBo First Hospital, Zhejiang, Ningbo, China, ¹⁴Department of Rheumatology and Immunology, Hebei General Hospital, Shijiazhuang, China, ¹⁵The 1st Affiliated Hospital of Guangzhou University of TCM, Guangzhou, China, ¹⁶Affiliated hospital of Guangdong medical University, Zhanjiang, China, ¹⁷Union Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China, ¹⁸Wuhan No 1 Hospital, wuhan, China, ¹⁹Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology, wuhan, China, ²⁰The Second Xiangya Hospital of Central South University, Changsha, China, ²¹Department of Rheumatology, First Affiliated Hospital of Medical University Of Anhui, Hefei, China, ²²The First Affiliated Hospital of Nanchang University, Nanchang, China, ²³Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China, ²⁴Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China
Background/Purpose: Adverse events (AE) during treatment in RA patients are unavoidable. Monitoring AEs in real time during long-term treatment is critical for AE detection and…
Abstract Number: 1329 • 2017 ACR/ARHP Annual Meeting
A Quantitative Framework for Evaluating Drug Combination Treatment in Rat Collagen-Induced-Arthritis Model
Amy Meng¹, Julie Di Paolo², Shringi Sharma³ and Anita Mathias³, ¹Clinical Pharmacology, Gilead Sciences, Foster City, CA, ²Immunology and Inflammation Biology, Gilead Sciences, Foster City, CA, ³Gilead Sciences, Foster City, CA
Background/Purpose: Filgotinib (FIL), a JAK1 inhibitor, and GS-9876, a SYK inhibitor, are currently being evaluated as once-daily monotherapy in subjects with rheumatoid arthritis (RA). A…
Abstract Number: 445 • 2015 ACR/ARHP Annual Meeting
Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from a Rheumatoid Arthritis Cohort
Arthur Lau¹, Mohammad Movahedi^2,3, Mark Tatangelo⁴, Claire Bombardier^3,5,6 and OBRI investigators, ¹Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Clinical Decision Making and Health Care, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, ⁶Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Clinical evidence suggests concomitant treatment with a biologic Disease-Modifying Antirheumatic Drug (bDMARD) and a conventional synthetic DMARD (csDMARD), especially with methotrexate (MTX) has greater…
Abstract Number: 2341 • 2014 ACR/ARHP Annual Meeting
The Combination Therapy of Cell Cycle Regulation Therapy Combined and TNF Blockade Ameliorated the Established Arthritis
Tadashi Hosoya^1,2, Kimito Kawahata¹, Hideyuki Iwai¹ and Hitoshi Kohsaka^2,3, ¹Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Japan Science and Technology Agency–CREST Program, Tokyo, Japan, ³Department of Rheumatology, Graduate School of Medical and Dental Sciences,, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
Background/Purpose The pathogenesis of rheumatoid arthritis (RA) is characterized by infiltration of inflammatory cells to the synovial tissues and their hyperplasia. Activated synovial fibroblasts become…
Abstract Number: 1330 • 2012 ACR/ARHP Annual Meeting
High Body Mass Index Is Associated with Decreased Response to Initial Combination Therapy in Recent Onset RA Patients
Marianne van den Broek¹, L. Heimans², S. le Cessie³, B. Siegerink³, H.K Ronday⁴, K.H. Han⁵, P.J.S.M. Kerstens⁶, T.W.J. Huizinga², W.F. Lems⁷ and C.F. Allaart², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Medical statistics and Epidemiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Rheumatology, MCRZ hospital, Rotterdam, Netherlands, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Rheumatology, VU University medical center, Amsterdam, Netherlands
High BMI is associated with decreased response to initial combination therapy in recent onset RA patients Background/Purpose: A diminished response to combination treatment with a fixed…
Abstract Number: 378 • 2012 ACR/ARHP Annual Meeting
Use of Anti-Tumor Necrosis Factor Monotherapy and Adherence with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs in Combination with Anti-Tumor Necrosis Factor Therapy Among Rheumatoid Arthritis Patients in a Real-World Setting
Nicole M. Engel-Nitz¹, Sarika Ogale² and Mahesh Kulakodlu¹, ¹Observational Research, OptumInsight, Eden Prairie, MN, ²Genentech, South San Francisco, CA
Background/Purpose: Studies have shown better response for anti-TNFs (aTNF) when they are used in combination with non-biologic DMARDs (nbDMARD), than when used as monotherapies.1 Therefore,…
Abstract Number: 383 • 2012 ACR/ARHP Annual Meeting
2002-04 Vs.2007-09: Initiation of Combination, and Tapering/Discontinuation (DC) Patterns of TNFi and MTX in a US (RA) Patient Registry: Analysis with CDAI Scores
Deborah Wenkert¹, Shannon Grant², David H. Collier³, Andrew S. Koenig⁴ and Joel M. Kremer⁵, ¹Inflammation TA, Amgen Inc., Thousand Oaks, CA, ²Axio Research LLC, Seattle, WA, ³Amgen Inc., Thousand Oaks, CA, ⁴Specialty Care, Pfizer Inc, Collegeville, PA, ⁵Center for Rheumatology, Albany Medical College, Albany, NY
Background/Purpose: We compared patient (pt) characteristics, for initiating, tapering and DC of TNFi/MTX combination therapy (CT), among RA pts seen during 02-04 vs. 07-09 to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].